Silybin as an anti-inflammatory and anti-fibrotic agent in cancer cachexia

水飞蓟宾作为癌症恶病质的抗炎和抗纤维化剂

• 批准号: 10665485
• 负责人: Mitzi Nagarkatti
• 金额: $ 17.86万
• 依托单位: UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-01 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10665485
• 关键词: Anti-Inflammatory Agents; Body Weight decreased; Cachexia; Cessation of life; Chronic Disease; Cicatrix; Deterioration; Fatty acid glycerol esters; Fibrosis; Health; Heart Diseases; Inflammation; Lead; Liver diseases; Locomotion; Malignant Neoplasms; Medicinal Plants; Milk Thistle; Muscle; Muscle function; Muscular Atrophy; Myopathy; Neuromuscular Diseases; Patients; Performance; Persons; Phase; Physical Function; Property; Quality of life; Skeletal Muscle; Tissues; Trauma; antifibrotic treatment; cancer cachexia; cancer therapy; dietary supplements; improved; muscle form; novel strategies; prevent; sarcopenia; silibinin; systemic inflammatory response; treatment response

Unintentional body weight loss (cachexia) in chronic diseases, such as cancer can lead to the deterioration of quality of life, lack of response to treatment, and ultimately death. Cancer cachexia is characterized by systemic inflammation, muscle and fat loss, and reduced physical function. Tissue fibrosis or scarring has been observed in cancer cachectic patients. Muscle fibrosis is one of the most consistent findings among people with reduced muscle function due to myopathies, neuromuscular disorders, trauma, and sarcopenia. Blocking inflammation and fibrosis in the pre-cachectic and cachectic stages is critical to positively impact muscle health, locomotion, and performance. Silybin, one of the active compounds of the medicinal plant Silybum marianum has shown anti-inflammatory and anti-fibrotic properties in cardiac and liver disorders. Since there are no approved therapies for cancer cachexia and silybin has been associated to improve factors associated with cachexia, we propose to assess whether silybin reduces skeletal muscle fibrosis. Furthermore, we will determine if TGF-􀈕 is involved in initiating or maintaining loss of muscle mass and function. Our findings could lead to the discovery of a new mechanism and novel strategies to prevent and/or treat cachexia.

慢性疾病（例如癌症）中无意的体重减轻（恶病质）可能导致 生活质量的恶化，对治疗的反应不足以及最终死亡。癌症恶病质是 以全身性炎症，肌肉和脂肪减少以及身体功能降低为特征。组织 在癌症化学患者中已经观察到纤维化或疤痕。肌肉纤维化是最多的 由于肌病，神经肌肉的肌肉功能降低的人的一致发现 疾病，创伤和肌肉减少症。阻塞炎症前和CACHEC的炎症和纤维化 阶段对于积极影响肌肉健康，运动和表现至关重要。 Silybin，其中之一 医疗厂的活性化合物Silybum Marianum已显示抗炎和抗纤维化 心脏和肝脏疾病的特性。由于没有批准的癌症疗法和 Silybin与改善与恶魔相关的因素有关，我们建议评估是否 甲硅烷基减少骨骼肌纤维化。此外，我们将确定TGF-◎是否参与了启动或 保持肌肉质量和功能的丧失。我们的发现可能导致发现新的 预防和/或治疗恶病质的机制和新型策略。